ALEXANDRIA, Va. — The international phase 3 DESTINY-Gastric04 clinical trial found that second-line treatment with trastuzumab deruxtecan (Enhertu®) can help people with advanced HER2-positive gastric ...

Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received at least one prior anti-HER2-based regimen either ...

Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received at least one prior anti-HER2-based regimen either ...

Hengrui Pharmaceutical's next battle: against the "fairy anti-cancer drug" DS-8201, competing for the 10 billion dollar ADC market. DATE: Sep 14 2024. Source of this article: Times Finance Author: Li ...

Hengrui Pharmaceutical's next battle: against the "fairy anti-cancer drug" DS-8201, competing for the 10 billion dollar ADC market_phoenix.com Finance_phoenix.com DATE: Sep 14 2024 Author: Li Aohua ...

Enter Enhertu, originally called DS-8201, a drug described as a tumor-selective cleavable linker that combines trastuzumab and a chemotherapy agent known as deruxtecan (DXd). “Our scientists in Tokyo ...

For the treatment of patients with HER2-amplified gastric cancers in addition to those with HER2 moderate-, low-, and non-expressing disease, trastuzumab deruxtecan (Enhertu; DS-8201) has shown to be ...

These include ENHERTU (T-DXd; DS-8201), a HER2 directed ADC, and datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2 directed ADC, which are being jointly developed and commercialized globally ...